143 related articles for article (PubMed ID: 37699444)
1. Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney.
Li J; Li XL; Li CQ
Am J Med Sci; 2023 Dec; 366(6):404-412. PubMed ID: 37699444
[TBL] [Abstract][Full Text] [Related]
2. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
3. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus.
Veron D; Villegas G; Aggarwal PK; Bertuccio C; Jimenez J; Velazquez H; Reidy K; Abrahamson DR; Moeckel G; Kashgarian M; Tufro A
PLoS One; 2012; 7(7):e40589. PubMed ID: 22808199
[TBL] [Abstract][Full Text] [Related]
4. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival.
Müller-Deile J; Worthmann K; Saleem M; Tossidou I; Haller H; Schiffer M
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1656-67. PubMed ID: 19828679
[TBL] [Abstract][Full Text] [Related]
5. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling.
Sison K; Eremina V; Baelde H; Min W; Hirashima M; Fantus IG; Quaggin SE
J Am Soc Nephrol; 2010 Oct; 21(10):1691-701. PubMed ID: 20688931
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
7. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K
BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
Tesařová P; Tesař V
Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
[TBL] [Abstract][Full Text] [Related]
10. Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling.
Kivelä R; Hemanthakumar KA; Vaparanta K; Robciuc M; Izumiya Y; Kidoya H; Takakura N; Peng X; Sawyer DB; Elenius K; Walsh K; Alitalo K
Circulation; 2019 May; 139(22):2570-2584. PubMed ID: 30922063
[TBL] [Abstract][Full Text] [Related]
11. VEGF inhibition and renal thrombotic microangiopathy.
Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of Dab2 is involved in inhibited VEGF-VEGFR-2 signaling induced by downregulation of syndecan-1 in glomerular endothelial cell.
Jing Z; Jia-Jun W; Wei-Jie Y
Cell Biol Int; 2020 Mar; 44(3):894-904. PubMed ID: 31868265
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease.
Logue OC; McGowan JW; George EM; Bidwell GL
Curr Opin Nephrol Hypertens; 2016 Sep; 25(5):404-9. PubMed ID: 27367910
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium.
Foster RR; Slater SC; Seckley J; Kerjaschki D; Bates DO; Mathieson PW; Satchell SC
Am J Pathol; 2008 Oct; 173(4):938-48. PubMed ID: 18772335
[TBL] [Abstract][Full Text] [Related]
15. VEGF-A
Stevens M; Neal CR; Salmon AHJ; Bates DO; Harper SJ; Oltean S
J Physiol; 2017 Oct; 595(19):6281-6298. PubMed ID: 28574576
[TBL] [Abstract][Full Text] [Related]
16. VEGF regulates local inhibitory complement proteins in the eye and kidney.
Keir LS; Firth R; Aponik L; Feitelberg D; Sakimoto S; Aguilar E; Welsh GI; Richards A; Usui Y; Satchell SC; Kuzmuk V; Coward RJ; Goult J; Bull KR; Sharma R; Bharti K; Westenskow PD; Michael IP; Saleem MA; Friedlander M
J Clin Invest; 2017 Jan; 127(1):199-214. PubMed ID: 27918307
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
19. Molecular controls of lymphatic VEGFR3 signaling.
Deng Y; Zhang X; Simons M
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775
[TBL] [Abstract][Full Text] [Related]
20. Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis.
Krebs R; Tikkanen JM; Ropponen JO; Jeltsch M; Jokinen JJ; Ylä-Herttuala S; Nykänen AI; Lemström KB
Am J Pathol; 2012 Nov; 181(5):1607-20. PubMed ID: 22959907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
